

Supplementary File 3 List of conference abstracts included in the systematic literature review

List of abstracts included in the review

1. López-Guzman, A, Prieto de Lamo G, Fraile A, Campos L, Azriel, S, Cornejo, J. Improvement of lipid profile in patients with type 2 diabetes treated with liraglutide. 2013.
2. A. Merchante AF, M. Tolosa, J. Ferrer, C. Sanchez. Efficacy and safety of replacing a dpp4-inhibitor by liraglutide in obese patients with type 2 diabetes mellitus and poor glycemic control. Presented at The World Diabetes Congress, Melbourne, 2-6 December 2013. 2013.
3. A. Penfornis PG, L. Martinez, S. Madani, G. Charpentier, E. Eschwège, J. Gautier. Effect of type 2 diabetes disease stage on liraglutide response in clinical practice: data from the EVIDENCE® study. Presented at The World Diabetes Congress, Melbourne, 2-6 December 2013. 2013.
4. A. Soto Gonzalez DBG, M. Buño Soto, M. Lopez De La Torre Casares. The liraglutide leads to not only improve glycemic control, but also cause liver inflammation of nonalcoholic fatty liver disease patients. 2013.
5. Abreu C, Gómez-Peralta, F, Castro, J, Alcarria, E, Cruz-Bravo, M, Llorente, M, Albornos, C, Moreno, C, Cepeda, M, Almodóvar, F. Influence of liraglutide treatment in obstructive sleep apnoea in obese type 2 diabetes patients. *Diabetologia*. 2014;57(1).
6. Al Busaidi N, Rizvi, Ali A, Montalto, Giuseppe, Patti, Angelo Maria, Castellino, Giuseppa, Bonfiglio, Amedeo, Giglio, Rosaria Vincenza, Nikolic, Dragana, Al-Waili, Khalid, Al-Maqbali, Ali, Al-Rasadi, Khalid, Rizzo, Manfredi. Liraglutide improves metabolic parameters and reduces carotid intima-media thickness in patients with type 2 diabetes : A 2-year prospective study. *Diabetes*. 2015;64.
7. Arcidiacono B. Glycemic Efficacy of Liraglutide Is Linked to Gender in Italian Type 2 Diabetic Patients. Presented at The American Diabetes Association (ADA) 74th Scientific Sessions, June 13-17, 2014, San Francisco, California. 2014.
8. A-Troncoso I, F-Mariño, Alexis, Sanchez-Sobrino, P, Riosprego, M, Carollo-Limeres, C, Cadarso-Suarez, C. Liraglutide in Routine Clinical Practice: Clinical Effectiveness and Potential Predictors of Treatment Response. *Diabetes*. 2014;63:A256.
9. Kawabe A, Miyashita Y, Matsumura M, Monden T, Banba N, Nakamoto, T. The Influence of GLP-1 Receptor Agonists on the Heart Rate Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability. 2015.
10. B. Vergès BB, B. Guiu, P. Buffier, S. Baillot-rudoni, M.-C. Brindisi, E. Crevisy, C. Fourmont, J.-P. Cercueil, J. Petit. Treatment with liraglutide leads to an important reduction in liver fat content, assessed by magnetic resonance spectroscopy, in people with type 2 diabetes. Presented at The EASD, 15-18 September, Stockholm, Sweden. 2015.
11. Bounthavong M, Tran J, Watanabe J, Chen T. Retrospective cohort study evaluating liraglutide and exenatide in a veteran population. Presented at ISPOR 18th Annual International Meeting, New Orleans, LA, USA, May 2013. 2013.
12. C. Morales Portillo MLL, M. Rivas Fernandez. Use of GLP-1 analogue (liraglutide) in 231 patients with diabetes: Andalusian multicenter study. Presented at The World Diabetes

Congress, Melbourne, 2-6 December 2013. 2013.

13. Cabanillas Lopez LF-M, P. Beato VÍbora, J. Diaz Pérez de Madrid, J. Acedo Hidalgo. Challenging in predicting response to liraglutide in real clinical practice. 2013.
14. CARLOS TRESCOLI MGZ, RICARDO BOU, ENCARNA DIAZ PUJOL. Long-Term Liraglutide Treatment in Elderly Diabetic Spanish Patients: Efficacy, Sustainability, Safety, and the Effect on Cardiovascular Risk Factors. Presented at The 75th Scientific Sessions American Diabetes Association (ADA), Boston, June5-9, 2015. 2015.
15. Charpentier G, Martinez, L, Eschwège, E, Madani, S, Penfornis, A, Gourdy, P, Gautier, JF. Efficacy of the human GLP-1 analogue liraglutide in patients with type 2 diabetes who switched from a DPP-4 inhibitor: 1-year data from the EVIDENCE study. *Diabetologia*. 2013;56(Suppl 1).
16. Chu J, Wei W, Buysman E, Thayer S, Brekke L, Crown WH, et al. Initiation of new injectable treatment introduced after anti-diabetic therapy with oral-only regimens (INITIATOR) study: an interim analysis. *Diabetologia* 2013;56(Suppl 1):S1-S566.
17. Crippa M, Camanini, S, Muraro, D, Agabiti Rosei, C, Zani, F, Ragni, G, Costa, R, Cerudelli, B. Effects of liraglutide on metabolic profile and 24-h ambulatory blood pressure in a group of type 2 diabetic -hypertensive patients. *High Blood Pressure and Cardiovascular Prevention*. 2014;21(4).
18. DeKoven M, Lee W, Bouchard J, Edwy M, Langer J. Improved Real-World Glycemic Outcomes With Liraglutide versus Other Incretin-Based Therapies in Type 2 Diabetes. Presented at The American Diabetes Association (ADA) 73rd Scientific Sessions, June 21-25, Chicago, Illinois 2013.
19. Diels J, Neslusan C. Comparative Persistency with Newer agents used to Treat Type 2 Diabetes (T2dm) In the united states: canagliflozin Versus Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors and Glucagon-Like Peptide-1 (Glp-1) agonists. *Value in Health*. 2015;18(3):A68-A9.
20. Elli P, Obert A, Casati S, Mauri C, Di Sacco G, Pellegrino D, Vignati, F, Muratori, F. Effect of 6 months liraglutide treatment on weight, glycemic and lipemic control in type 2 diabetes. *Eating and Weight Disorders*. 2014;19(3).
21. F. Gomez-Peralta CA, J. Castro, E. Alcarria, M. Cruz-Bravo, M. Llorente, C. Albornos, C. Moreno, M. Cepeda, F. Almodovar. Influence of liraglutide treatment in obstructive sleep apnea(OA) in patients with obesity and diabetes mellitus type 2 2013.
22. Farah L, Gourdy P, Charpentier G, Martinez L, Eschwege E, Penfornis A, et al. Effectiveness of Switching from a DPP-4 Inhibitor to the Human GLP-1 Analogue Liraglutide in Patients with Type 2 Diabetes. *Canadian Journal of Diabetes*. 2014;38(5):S46.
23. Fatima J, Pearce S. The use of GLP-1 agonist liraglutide : Adhering to guidelines? *Diabetic Medicine*. 2014;31.
24. Fattor B, Cretti, A, Cristini, M, Lintner, S, Monauni, T, Orion, G, Telfser, C, Zardi, F. Treatment with GLP-1 analogue liraglutide is associated with improvement in HbA1c and weight loss in type 2 diabetic patients after early metformin failure. *Pharmacotherapy*. 2011;31(10).
25. Fernandez Garcia JC, Cortes Salazar, C.M, Aranda, P. Liraglutide decreases microalbuminuria and blood pressure in hypertensive obese patients with type 2 diabetes. *Journal of*

Hypertension. 2015;33(e-Supplement-1):e1777.

26. F-Mariño A, A-Troncoso, Isabel, Carollo-Limeres, C, Cadarsosuares, C. Cardiovascular risk mitigation in type 2 diabetes patients treated with liraglutide. *Diabetes*. 2014;63.
27. Fujii H, Kato, Mitsutoshi, Kato, Noriko, Kanno, Kazuo, Kondo, Hiroko, Takamura, Hiroshi, Matsuda, Daisuke, Shigeta, Masayuki, Watanabe, Yuko, Miyakawa, Takaichi, Ueki, Akio, Kitaoka, Takafumi. Withdrawing GLP-1 analog, liraglutide on drug-naive type 2 diabetes patients - Does it induce glycemic remission? *Diabetes*. 2013;62.
28. G. Charpentier LM, E. Eschwège, S. Madani, A. Penfornis, P. Gourdy, J. Gautier. One-year data from EVIDENCE®: sub-analysis of effectiveness of liraglutide in patients switched from a DPP-4 inhibitor. Presented at The World Diabetes Congress, Melbourne, 2-6 December 2013. 2013.
29. G. Piedrola DC, C. Gil Anguita. Evolution of adrenal steroids in men with type 2 diabetes with liraglutide - relationship with insulin sensitivity. 2013.
30. Ganz M. Real-World Clinical Effectiveness of Liraglutide in Type 2 Diabetes Patients Aged 65 Years and Above in the U.S. Presented at The American Diabetes Association (ADA) 74th Scientific Sessions, June 13-17, 2014, San Francisco, California. 2014.
31. Gonzalez Molero I, Garcia Arnés, J, Dominguez Lopez, M, Vallejo, R, Gonzalo, M. Efficacy and safety evaluation of liraglutide treatment in morbid obese and diabetic patients in first year of commercialization in Spain. 2013;15.
32. Gorgojo-Martinez JJ, Feo-Ortega, Gara, Serrano-Moreno, Clara. Effectiveness and safety of liraglutide in patients with weight regain and persistence of type 2 diabetes mellitus after bariatric surgery. *Diabetes*. 2015;64.
33. Gourdy P, Penfornis A, Charpentier G, Madani S, Martinez L, Eschwège E, et al. Effectiveness and tolerability with liraglutide among patients with type 2 diabetes. 1-year data from EVIDENCE: a 2-year, prospective, follow-up, post-marketing study. Presented at the EASD, 24-27th September, Barcelona, Spain. 2013.
34. Grabner M, Wei W, Raparla S, Quimbo RA, Cziraky MJ, Thayer SW, et al. Real-world comparative effectiveness analysis of patients initiating injectable treatments for type 2 diabetes mellitus (T2DM): Pilot data from the INITIATOR study. *Value in Health*. 2012;15(7):A494.
35. H. Shimizu HK, H. Akiyama, K. Uehara, K. Kashima, K. Kawada, T. Onai. Switching to liraglutide from insulin improves glycaemic control with a reduction of body weight: association with pre-switching BMI. 2013.
36. Heymann A, Maor Y, Goldstein I, Todorava L, Schertz-Sternberg P, Karasik A. Real life evidence of Liraglutide effects supports efficacy shown in RCTs. Presented at The World Diabetes Congress, Melbourne, 2-6 December 2013. 2013.
37. Htike ZZ, Gangat, I, McNally, PG, Davies, M.J, Lawrence, I.G. Liraglutide with or without previous exenatide in real-life clinical practice. *Diabet Med*. 2011;28.
38. Imamura S, Hirai, K. Hirai. A. A Novel Therapeutic use of Liraglutide for the Prevention of Progression of Overt Diabetic Nephropathy in Patients with Type 2 Diabetes. Presented at the American Diabetes Association (ADA) 73rd Scientific Sessions. June 21 - 25, 2013; Chicago,

Illinois. 2013.

39. J. Doupis AK, C. Kallinikou, V. Papandreopoulou, N. Tentolouris. Liraglutide reduces the need of frequent self blood glucose monitoring in both insulin and oral agents treated patients with type 2 Diabetes. 2013.
40. JEAN-FRANÇOIS GAUTIER AP, GUILLAUME CHARPENTIER, AMIRA BOUZIDI, SULIYA MADANI, LUC MARTINEZ, EVELINE ESCHWÈGE, PIERRE GOUR. The Proportion of Patients Successfully Treated with Liraglutide—Results from a Post-hoc Analysis of the EVIDENCE Study. 2015.
41. JUAN J. GORGOJO-MARTINEZ CS-M, GARA FEO-ORTEGA. Effect of Renal Impairment on the Effectiveness and Safety of Two GLP-1 Receptor Agonists, Exenatide, and Liraglutide in Patients with Type 2 Diabetes. Presented at the ADA, Boston, June 6-9, 2015. 2015.
42. K. Nakamura AY, K. Nakata. Fasting serum C-peptide and age is a useful predictor of successful liraglutide monotherapy in Japanese type 2 diabetes patients. 2013.
43. K. Thong PSG, R. Ryder. The efficacy of exenatide and liraglutide among South Asians in the Association of British Clinical Diabetologists nationwide audits. 2013.
44. Karasik A, Heymann A, Sternberg P, Leshno M, Todorova L, Goldshtein I, et al. Real life effects of liraglutide supports those shown in RCTs. Presented at The ISPOR 16th Annual European Congress, 2-6th November 2013, Dublin.
45. Katagiri N, Kaneko S, Tahara Y, Sato Y, Hamano K. Perioperative Liraglutide Therapy for Japanese Subjects With T2DM. Diabetes 2013;62.
46. Lecube A, Gutierrez L, Lopez C, Sanchez E. What Happened with Patients Who Initiated Treatment with the Human GLP-1 Analogue Liraglutide More than 2 Years Ago? Diabetes. 2015;64.
47. Lecube A, Gutierrez L, Lopez C, Sanchez E. What Happened with Patients Who Initiated Treatment with the Human GLP-1 Analogue Liraglutide More than 2 Years Ago? Presented at The American Diabetes Association (ADA) 75th Scientific Sessions., June 5 - 9, 2015; Boston, Massachusetts. 2015.
48. Levin P, Wei W, Buysman E, Thayer S, Brekke L, Crown WH, et al. The INITIATOR study: Real-world treatment patterns and outcomes in patients with type 2 diabetes initiating insulin glargine or liraglutide. Diabetologia. 2014;57(Suppl 1):S1-S566.
49. Lorenz M, Owens D, Raccach D, Roy-Duval C, Lawson F, Lehmann A, et al. Differential Effects of GLP-1 Receptor Agonists on 24-Hour Averaged Heart Rate in Healthy Volunteers and Patients with Type 2 Diabetes. 2015.
50. M. Monreal DA, J. Acha, P. De Castro, M. Gracia, A. Sanz, P. Trincado, R. Albero. Evolution of clinics and biochemists parameters in patients treated with liraglutide. Presented at The World Diabetes Congress, Melbourne, 2-6 December 2013. 2013.
51. M. Núñez Sánchez RSS, C. del Peso, M. Gallego García, N. García-Talavera Espín, M. Gómez Sánchez, T. Monedero Saiz, A. Meoro Avilés, J. Soriano Palao. Optimization of liraglutide treatment in obese patients with type 2 diabetes resistant to conventional treatment. Presented at The World Diabetes Congress, Melbourne, 2-6 December 2013. 2013.
52. Madani S, Charpentier G, Martinez, L, Eschwège, E, Penfornis, A, Gourdy, P, Gautier JF.

Effectiveness of switching from a DPP-4 inhibitor to the human GLP-1 analogue liraglutide in patients with type 2 diabetes : Data from the EVIDENCE study. *Diabetologia*. 2014;57(1):S1-S566.

53. Martínez L, Gourdy P, Eschwège E, Madani S, Charpentier G, Penfornis A, et al. Baseline observations from the EVIDENCE Study: characteristics of type 2 diabetes patients initiating liraglutide. *Primary Care Diabetes*. 2013;7(1):77.
54. Matsson P, Lind M, Johansson G, Svenningsson I, Jörgensen L, Ploug U, et al. A retrospective assessment of clinical effectiveness in type 2 diabetes patients treated with liraglutide or sitagliptin from primary care centers in Sweden. Presented at The SFD 7-8 May 2015. 2015.
55. Mcadam-Marx C, Nguyen, Hiep, Schauerhamer, Marisa, Ye, Xiangyang, Singhal, Mukul, Cobden, David. Real-world 1-year HbA1c and weight outcomes in patients treated with exenatide once weekly or liraglutide once daily. *Diabetes*. 2014;64.
56. McEwan P, Evans, ML, Nyeland, ME, Skovgaard R, Richards A, Bergan, E.Q, Demuth, D, Alvarez, L Garcia, Muthutantri, A, Ploug, UJ. Impact of UK guidelines on clinical prescribing in patients with Type 2 diabetes: a comparative effectiveness analysis of liraglutide vs sitagliptin in the UK. *Diabet Med*. 2014;31(Suppl 1):28-123.
57. Mohan V, Kannan, A, Jebarani, S. A retrospective analysis of the effect of liraglutide in asian indian patients with type 2 diabetes with proteinuria. *Diabetes*. 2012;61(A569).
58. Muñoz-Torres M, San Juan-McNulty A, Muñoz-Martín A, Cobo-Fernández M, Carrillo-Mendigaño D, Avilés- Perez M. Treatment persistence with liraglutide in patients with type 2 diabetes followed in an endocrinology unit. Presented at The World Diabetes Congress, Melbourne, 2-6 Dec, 2013. 2013.
59. Nakadaira I, Hamano, K, Katagiri, Y, Tahara, Y, Sato, Y, Kaneko, S. Liraglutide is applicable in elective perioperative patients with type 2 diabetes. *Diabetologia*. 2013;56(Suppl 1):S1-S566.
60. OSHINOBU KONDO SS, URU NEZU. OSADA, YASUO TERAUCHI. Exenatide BID Improves β -Cell Function More than Liraglutide QD in Patients with Type 2 Diabetes: A Propensity Score Matched Retrospective Cohort Study (ELENA- β). 2015.
61. P. Mezquita-Raya MLdITC, O. Moreno Pérez, D. Diabetes WorkGroup. Liraglutide in patients with DM2 and obesity previously treated with oral antidiabetic agents: eDM Spain SEEN Study. 2013.
62. P. Senior JV, K. Jindal. Effect of liraglutide on metabolic and renal outcomes over 12 months in community diabetic nephropathy clinic. 2013.
63. Patti AM, Rizzo, M, Giglio, R.V, Tamburello, A, Pecoraro, G, Giannone, V, Rizvi, A.A, Montalto, G. Beneficial effects of liraglutide on carotid intima-media thickness in patients with type 2 diabetes : A 8-month prospective study. *Ultraschall in der Medizin, Supplement*. 2013;34.
64. Sen Gupta P, Thong KY, Armstrong M, Newsome PN, Winocour P, Ryder R. Does Liraglutide Therapy Affect the Metabolic Response in Patients with Elevated Alanine Aminotransferase and Type 2 Diabetes Mellitus?: The ABCD Nationwide Liraglutide Audit. 2013. *Diabetes* 2013; 62 (Suppl. 1): 1037P
65. R. Darias BG, B. Gómez, B. Rivero, J. Rodríguez, A. Mora, J. Oliva, I. Llorente. Changes in clinical and analytical parameters in a group of patients treated with liraglutide during 6 months.

Presented at The World Diabetes Congress, Melbourne, 2-6 December 2013. 2013.

66. Giglio RV, Rizzo, M, Patti AM, Nikolic D, Di Bartolo V, Castellino, G, et al. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and nonalcoholic fatty liver disease: an 8-month prospective pilot study. Presented at The EASD, Vienna, Austria, 16-19 September. 2014.
67. Raparla S, Wei W, Grabner M, Cuddihy R, Hu W, Quimbo RA. Real-world practice patterns, clinical and economic outcomes among us patients with type 2 diabetes initiating once-daily injectable pen therapy with insulin glargine or liraglutide. *J Gen Intern Med.* 2012;27(S293).
68. Rizzo M, Patti, AM, Maria P, Angelo DB, Vittora C, et al. Effect of liraglutide on carotid intima-media thickness in patients with type - 2 diabetes : A 4-month prospective study. *Diabetes.* 2012;61.
69. Rizzo M, Ferlita A, Nikolic D, Maria P, Angelo DB, Vittora C, et al. Effects of liraglutide on metabolic parameters and carotid intima-media thickness in patients with the metabolic syndrome: A 12-month prospective pilot study. *Diabetes.* 2014;63.
70. Rozas-Moreno P, Castro-Giménez J, Sáenzgutiérrez A, Moreno-Fernández J, Lozano-Suárez C, Aguirre-Sánchez-Covisa, M. The liraglutide effect in ambulatory blood pressure monitoring in type 2 diabetes mellitus patients: A proof-of-concept study. *Diabetes.* 2015;64.
71. Saunders W, Nguyen H, Kalsekar, I. Real-world comparative effectiveness of exenatide once weekly and liraglutide in patients with type 2 diabetes mellitus. *Diabetes.* 2014;63:828.
72. Sharma M, Healy, P, Drews M, Jacobs M. The effects of adding liraglutide to an urban type 2 diabetic population. *Pharmacotherapy.* 2011;31(10):439.
73. Smith CJ, Drummond, R.S. An observational study of the effect of incretin therapies upon cardiovascular risk in Type 2 diabetes. *Diabet Med.* 2012;29.
74. Sotiropoulos A, Papazafiropoulou A, Kokolaki A, Kardara M, Apostolou O, Bousboulas S, et al. Effects of liraglutide on cardiovascular risk factors in patients with type 2 diabetes mellitus. *Diabetes.* 2013;62.
75. Sullivan C, Gaoatswe G, Gibney J, Louise H, Doran, M, Kane D, et al. Treatment with the glucagon-like peptide-1 analogue liraglutide is associated with amelioration of disease activity in a prospective cohort study of patients with inflammatory arthritis. *Arthritis Rheum.* 2013;65 Suppl 10: 1484.
76. Thayer S, Wei W, Brekke L, Buysman E, Hu W, Cuddihy R. How different were they? A retrospective study of real-world U.S. Patients with Type 2 Diabetes Mellitus (T2DM) Initiating once-daily injectable pen therapy with insulin glargine or liraglutide. *Endocrine Reviews.* 2012;33(3).
77. Widdowson WM, Gibney, J. Liraglutide usage, efficacy and tolerance: A retrospective audit of clinical practice, AMNCH 2009-2010. *Irish Journal of Medical Science.* 2011;180:S494.
78. Xie L, Wei W, Thayer S, Brekke L, Buysman E, Crown W, et al. Insulin or GLP-1? A Real-World Comparative Effectiveness Analysis of Initiating Injectable Treatment Among Patients With Type 2 Diabetes Mellitus Failing Oral Antidiabetic Drugs: Pilot Data From the INITIATOR Study. Presented at The Endocrine Society's 95th Annual Meeting and Expo, June 15–18, 2013 - San

Francisco. Diabetes & Obesity Management. 2013;34(3).

79. Zografou I, Griva T, Papadopoulou D, Anyfanti P, Nikolaidou B, Lazaridis A, et al. Predictors of response to treatment with liraglutide in patients with type 2 diabetes. Diabetes. 2015;64.
80. Zografou I, Griva T, Papadopoulou D, Anyfanti P, Nikolaidou B, Lazaridis A, et al. Predictors of response to treatment with liraglutide in patients with type 2 diabetes. Presented at The American Diabetes Association (ADA) 75th Scientific Sessions, June 5-9, 2015; Boston, Massachusetts. 2015.
81. Katagiri N, Kaneko S, Tahara Y, Sato Y, Hamano K. Perioperative liraglutide therapy for Japanese subjects with T2DM. Presented at the American Diabetes Association (ADA) 73rd Scientific Sessions. June 21-25, 2013; Chicago, Illinois. 2013.